Últimas noticias sobre TG Therapeutics (NASDAQ:TGTX) Bolsa

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics Inc

Preliminary Fourth Quarter and Full Year 2024 Updates: BRIUMVI U.S. net product revenue expected to be $103.6M and $310M for the fourth quarter and...

TG Therapeutics sees Q4 BRIUMVI U.S. net product revenue $103.6M

2025 Target Guidance: Full Year 2025 target total global revenue of approximately $540M, including BRIUMVI U.S. net product revenue of approximatel...

TG Therapeutics targets FY25 global revenue $540M, consensus $537.84M

TG Therapeutics says 2024 Briumvi sales topped expectations

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price...

B.Riley Financial Reaffirms Their Buy Rating on TG Therapeutics (TGTX)

TG Therapeutics ( ($TGTX) ) has provided an update. On January 14, 2025, TG Therapeutics announced preliminary U.S. net product revenue for BRIUMVI...

TG Therapeutics Reports Strong Revenue and Future Goals

ClearBridge Small Cap Growth Fund Q4 2024 Commentary

H.C. Wainwright analyst Edward White has reiterated their bullish stance on TGTX stock, giving a Buy rating yesterday. Edward White has given his B...

Strong Financial Outlook and Strategic Growth Opportunities Bolster Buy Rating for TG Therapeutics

TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade)

Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +

What Moved Markets This Week

AEHR

APPTF

BIZD

BLDR

CASY

CPRX

FOUR

GILD

HLNE

HWAIF

INTC

MRNA

MSTR

NMIH

OSCR

PFLT

RBRK

RCUS

RHHBY

SGRY

SPGYF

SRPT

TGTX

TLRY

UPST

VRNS

WING

XMTR

Press Releases

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

News

TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update

Earnings

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

FUJIFILM Diosynth Biotechnologies Signs Manufacturing Supply Agreement with TG Therapeutics

TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

TG Therapeutics to Participate in the Evercore HealthCONx Conference

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Health Care

TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue and 2025 Anticipated Development Milestones

ADMA

ADNT

AMCX

CHCT

CSWI

CVGW

DELL

EHAB

ERIE

ETSY

HELE

INSP

MERC

PGNY

PLTR

RILY

SPGI

TGNA

VNOM

VREX

WOLF

ZEUS

Arcellx

ADMA Biologics

Alkermes

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

HC Wainwright & Co.

JP Morgan

Goldman Sachs

TD Cowen

B. Riley Securities

Comments

TG Therapeutics

Noticias

Últimas noticias sobre TG Therapeutics (NASDAQ:TGTX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL